SOST and osteoporosis: A recently created anti-osteoporosis medication called Romosozumab, the first sclerostin inhibitor licensed by the U.S. FDA, targets sclerostin, has demonstrated remarkable effectiveness in treating postmenopausal osteoporosis (190).